216 related articles for article (PubMed ID: 23640356)
1. Femoropopliteal in-stent restenosis: review and potential for drug based therapy.
Phillips J; Ansel G
J Cardiovasc Surg (Torino); 2013 Jun; 54(3):333-6. PubMed ID: 23640356
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials.
Cassese S; Byrne RA; Ott I; Ndrepepa G; Nerad M; Kastrati A; Fusaro M
Circ Cardiovasc Interv; 2012 Aug; 5(4):582-9. PubMed ID: 22851526
[TBL] [Abstract][Full Text] [Related]
3. The endovascular approach for in-stent restenosis in femoropopliteal disease.
Cannavale A; Tsetis D; Krokidis M
Expert Rev Cardiovasc Ther; 2015 Apr; 13(4):391-401. PubMed ID: 25761905
[TBL] [Abstract][Full Text] [Related]
4. First- and second-generation drug-eluting balloons for femoro-popliteal arterial obstructions: update of technique and results.
De Vries JP; Karimi A; Fioole B; Van Leersum M; Werson DA; Van Den Heuvel DA
J Cardiovasc Surg (Torino); 2013 Jun; 54(3):327-32. PubMed ID: 23640355
[TBL] [Abstract][Full Text] [Related]
5. Drug eluting balloons.
Diehm NA; Hoppe H; Do DD
Tech Vasc Interv Radiol; 2010 Mar; 13(1):59-63. PubMed ID: 20123434
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel-eluting stents for the treatment of femoropopliteal arterial stenoses: focus on the Zilver PTX drug-eluting peripheral stent.
Moukarbel GV; Burket MW
Expert Rev Med Devices; 2015 Mar; 12(2):157-62. PubMed ID: 25418344
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial.
Werk M; Langner S; Reinkensmeier B; Boettcher HF; Tepe G; Dietz U; Hosten N; Hamm B; Speck U; Ricke J
Circulation; 2008 Sep; 118(13):1358-65. PubMed ID: 18779447
[TBL] [Abstract][Full Text] [Related]
8. Standard balloon angioplasty versus angioplasty with paclitaxel-eluting balloons for femoropopliteal artery stenosis.
Ju MH; Rodríguez HE
J Cardiovasc Surg (Torino); 2012 Aug; 53(4):459-63. PubMed ID: 22854525
[TBL] [Abstract][Full Text] [Related]
9. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E
J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
[TBL] [Abstract][Full Text] [Related]
10. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience.
Dick P; Sabeti S; Mlekusch W; Schlager O; Amighi J; Haumer M; Cejna M; Minar E; Schillinger M
Radiology; 2008 Jul; 248(1):297-302. PubMed ID: 18566179
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of endovascular treatment strategies on in-stent restenosis of femoropopliteal artery lesions].
Fu WG; Yue JN
Zhonghua Wai Ke Za Zhi; 2016 Aug; 54(8):586-90. PubMed ID: 27502131
[TBL] [Abstract][Full Text] [Related]
12. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
Jaff MR; Rosenfield K; Scheinert D; Rocha-Singh K; Benenati J; Nehler M; White CJ
Am Heart J; 2015 Apr; 169(4):479-85. PubMed ID: 25819854
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of paclitaxel drug-coated balloon in femoropopliteal in-stent restenosis.
Anantha-Narayanan M; Love K; Nagpal S; Sheikh AB; Regan CJ; Mena-Hurtado C
Expert Rev Med Devices; 2020 Jun; 17(6):533-539. PubMed ID: 32525406
[TBL] [Abstract][Full Text] [Related]
14. Peripheral drug-eluting technology.
Franzone A; Stabile E; Trimarco B; Esposito G
Cardiol Clin; 2015 Feb; 33(1):151-62. PubMed ID: 25439337
[TBL] [Abstract][Full Text] [Related]
15. Drug coated balloons in the superficial femoral artery.
Schlager O; Gschwandtner ME; Willfort-Ehringer A; Wolf F; Loewe C; Koppensteiner R; Lichtenberg M
J Cardiovasc Surg (Torino); 2018 Feb; 59(1):60-69. PubMed ID: 28933522
[TBL] [Abstract][Full Text] [Related]
16. Past, present and future of femoropopliteal stenting.
Schillinger M; Minar E
J Endovasc Ther; 2009 Feb; 16 Suppl 1():I147-52. PubMed ID: 19317587
[TBL] [Abstract][Full Text] [Related]
17. Drug-Coated Balloons as the New Standard of Care for Femoropopliteal In-Stent Restenosis: FAIR Assumption?
Laird JR; Singh GD
Circulation; 2015 Dec; 132(23):2198-200. PubMed ID: 26446729
[No Abstract] [Full Text] [Related]
18. Eluvia drug-eluting vascular stent system for the treatment of symptomatic femoropopliteal lesions.
Müller-Hülsbeck S; Hopf-Jensen S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J; Gray WA
Future Cardiol; 2018 May; 14(3):207-213. PubMed ID: 29631434
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of Usefulness of Drug Coated Balloon Versus Standard Balloon in the Treatment of Femoropopliteal In-Stent-Restenosis.
Doshi R; Kumar A; Adalja D; Vaz I; Shariff M
Am J Cardiol; 2020 Oct; 133():170-171. PubMed ID: 32778336
[No Abstract] [Full Text] [Related]
20. 12-month primary patency rates of contemporary endovascular device therapy for femoro-popliteal occlusive disease in 6,024 patients: beyond balloon angioplasty.
Marmagkiolis K; Hakeem A; Choksi N; Al-Hawwas M; Edupuganti MM; Leesar MA; Cilingiroglu M
Catheter Cardiovasc Interv; 2014 Oct; 84(4):555-64. PubMed ID: 24740749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
